Incidence of allergic reaction adverse events during adjunctive treatment with eslicarbazepine acetate in patients with refractory partial-onset seizures: a pooled analysis of three Phase III placebo-controlled studies

JOANNE ROGIN,TREVOR RESNICK, LAURA STROM, ELINOR BEN-MENACHEM, SILVIA KOCHEN, DAVID BLUM, HELENA GAMA, PATRÍCIO SOARES-DA-SILVA, TODD GRINNELL

Philadelphia

Congreso; 66th American Academy of Neurology Annual Meeting; 2014

American Academy of Neurology

Rash is recognized as an adverse effect of antiepileptic drug (AED) treatment.1 ?? Relatively high rates of rash have been observed with phenytoin, lamotrigine and carbamazepine. ?? Relatively low rates of rash have been observed with levetiracetam, gabapentin and valproic acid. ? Serious skin rashes such as Stevens-Johnson syndrome and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) may also result from AED use.2,3 ? Eslicarbazepine acetate (ESL, Aptiom®) is a once-daily (QD) oral AED, approved by the US Food and Drug Administration in November 2013 as adjunctive treatment of partial-onset seizures (POS). ESL (Zebinix®) was approved by the European Medicines Agency in 2009 for adjunctive therapy in adults with POS with or without secondary generalization. ? ESL is extensively and rapidly converted to eslicarbazepine after oral administration.4,5 ? Further investigation into the incidence of rash among patients treated with ESL would be of value